Relationship Between Anti-SARS-CoV-2 S Abs and IFN-λ3 Levels in the Administration of Oxygen Following COVID-19 Vaccination

Overview

Journal Immunohorizons

Specialty Allergy & Immunology

Date 2023 Jan 16

PMID 36645852

Authors

Yuichiro Takeshita

Yasuo To

Yusuke Kurosawa

Toru Kinouchi

Kota Tsuya

Yuji Tada

Kenji Tsushima

Affiliations

Soon will be listed here.

Abstract

Although the effectiveness of vaccination at preventing hospitalization and severe coronavirus disease (COVID-19) has been reported in numerous studies, the detailed mechanism of innate immunity occurring in host cells by breakthrough infection is unclear. One hundred forty-six patients were included in this study. To determine the effects of vaccination and past infection on innate immunity following SARS-CoV-2 infection, we analyzed the relationship between anti-SARS-CoV-2 S Abs and biomarkers associated with the deterioration of COVID-19 (IFN-λ3, C-reactive protein, lactate dehydrogenase, ferritin, procalcitonin, and D-dimer). Anti-S Abs were classified into two groups according to titer: high titer (≥250 U/ml) and low titer (<250 U/ml). A negative correlation was observed between anti-SARS-CoV-2 S Abs and IFN-λ3 levels (r = -0.437, p < 0.001). A low titer of anti-SARS-CoV-2 S Abs showed a significant association with oxygen demand in patients, excluding aspiration pneumonia. Finally, in a multivariate analysis, a low titer of anti-SARS-CoV-2 S Abs was an independent risk factor for oxygen demand, even after adjusting for age, sex, body mass index, aspiration pneumonia, and IFN-λ3 levels. In summary, measuring anti-SARS-CoV-2 S Abs and IFN-λ3 may have clinical significance for patients with COVID-19. To predict the oxygen demand of patients with COVID-19 after hospitalization, it is important to evaluate the computed tomography findings to determine whether the pneumonia is the result of COVID-19 or aspiration pneumonia.

References

Chemaitelly H, Tang P, Hasan M, Almukdad S, Yassine H, Benslimane F . Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. N Engl J Med. 2021; 385(24):e83. PMC: 8522799. DOI: 10.1056/NEJMoa2114114. View

Riester E, Findeisen P, Hegel J, Kabesch M, Ambrosch A, Rank C . Performance evaluation of the Roche Elecsys Anti-SARS-CoV-2 S immunoassay. J Virol Methods. 2021; 297:114271. PMC: 8393518. DOI: 10.1016/j.jviromet.2021.114271. View

Alanagreh L, Alzoughool F, Atoum M . The Human Coronavirus Disease COVID-19: Its Origin, Characteristics, and Insights into Potential Drugs and Its Mechanisms. Pathogens. 2020; 9(5). PMC: 7280997. DOI: 10.3390/pathogens9050331. View

Tartof S, Slezak J, Fischer H, Hong V, Ackerson B, Ranasinghe O . Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet. 2021; 398(10309):1407-1416. PMC: 8489881. DOI: 10.1016/S0140-6736(21)02183-8. View

Stumpf J, Siepmann T, Lindner T, Karger C, Schwobel J, Anders L . Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: A prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine. Lancet Reg Health Eur. 2021; 9:100178. PMC: 8299287. DOI: 10.1016/j.lanepe.2021.100178. View

Meyer B, Torriani G, Yerly S, Mazza L, Calame A, Arm-Vernez I . Validation of a commercially available SARS-CoV-2 serological immunoassay. Clin Microbiol Infect. 2020; 26(10):1386-1394. PMC: 7320699. DOI: 10.1016/j.cmi.2020.06.024. View

Kawamura K, Osawa A, Tanimoto M, Itoh N, Matsuura T, Kondo I . Prediction of the possibility of return to home based on frailty assessment at the time of admission to the COVID-19 treatment unit. Geriatr Gerontol Int. 2022; 22(9):815-817. PMC: 9538938. DOI: 10.1111/ggi.14460. View

Suzuki T, Iwamoto N, Tsuzuki S, Kakumoto Y, Suzuki M, Ashida S . Interferon lambda 3 in the early phase of coronavirus disease-19 can predict oxygen requirement. Eur J Clin Invest. 2022; 52(9):e13808. PMC: 9541409. DOI: 10.1111/eci.13808. View

Pestka S . The interferons: 50 years after their discovery, there is much more to learn. J Biol Chem. 2007; 282(28):20047-51. DOI: 10.1074/jbc.R700004200. View

10.

Muller M, Tomlinson G, Marrie T, Tang P, McGeer A, Low D . Can routine laboratory tests discriminate between severe acute respiratory syndrome and other causes of community-acquired pneumonia?. Clin Infect Dis. 2005; 40(8):1079-86. PMC: 7107805. DOI: 10.1086/428577. View

11.

Yang J, L Petitjean S, Koehler M, Zhang Q, Dumitru A, Chen W . Molecular interaction and inhibition of SARS-CoV-2 binding to the ACE2 receptor. Nat Commun. 2020; 11(1):4541. PMC: 7486399. DOI: 10.1038/s41467-020-18319-6. View

12.

Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E . Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. N Engl J Med. 2022; 386(16):1532-1546. PMC: 8908811. DOI: 10.1056/NEJMoa2119451. View

13.

Takei S, Ai T, Yamamoto T, Igawa G, Kanno T, Tobiume M . Performance evaluation of the Roche Elecsys® Anti-SARS-CoV-2 immunoassays by comparison with neutralizing antibodies and clinical assessment. PLoS One. 2022; 17(9):e0274181. PMC: 9477342. DOI: 10.1371/journal.pone.0274181. View

14.

Thomas S, Moreira Jr E, Kitchin N, Absalon J, Gurtman A, Lockhart S . Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. N Engl J Med. 2021; 385(19):1761-1773. PMC: 8461570. DOI: 10.1056/NEJMoa2110345. View

15.

Nahm F . Receiver operating characteristic curve: overview and practical use for clinicians. Korean J Anesthesiol. 2022; 75(1):25-36. PMC: 8831439. DOI: 10.4097/kja.21209. View

16.

Cai Y, Zhang J, Xiao T, Peng H, Sterling S, Walsh Jr R . Distinct conformational states of SARS-CoV-2 spike protein. Science. 2020; 369(6511):1586-1592. PMC: 7464562. DOI: 10.1126/science.abd4251. View

17.

Kanda Y . Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2012; 48(3):452-8. PMC: 3590441. DOI: 10.1038/bmt.2012.244. View

18.

Sugiyama M, Kinoshita N, Ide S, Nomoto H, Nakamoto T, Saito S . Serum CCL17 level becomes a predictive marker to distinguish between mild/moderate and severe/critical disease in patients with COVID-19. Gene. 2020; 766:145145. PMC: 7489253. DOI: 10.1016/j.gene.2020.145145. View

19.

Duzgun S, Durhan G, Basaran Demirkazik F, Akpinar M, Ariyurek O . COVID-19 pneumonia: the great radiological mimicker. Insights Imaging. 2020; 11(1):118. PMC: 7681181. DOI: 10.1186/s13244-020-00933-z. View

20.

Rauch S, Jasny E, Schmidt K, Petsch B . New Vaccine Technologies to Combat Outbreak Situations. Front Immunol. 2018; 9:1963. PMC: 6156540. DOI: 10.3389/fimmu.2018.01963. View